Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, A.W.S. Ritchie et al.|The Lancet|2015Cited by 2k
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth Woods, Mark Sculpher, E.G. Sideris et al.|European Urology Oncology|2018Cited by 27
SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.Robert J. Jones, Simon J. Crabb, Amit Bahl et al.|Journal of Clinical Oncology|2021Cited by 3